A77 1726

ALX-430-096

Datasheet
Manual
SDS
CofA

Already have an account?

Dihydrorotate dehydrogenase inhibitor

Physiologically active metabolite of the immunosuppressive drug leflunomide (Prod. No. ALX-430-095). Inhibits the activity of dihydrorotate dehydrogenase and of protein tyrosine kinases. Blocks TNF-mediated NF-κB activation in a dose- and time-dependent manner. Also inhibits the activity of cyclooxygenase-2 (COX-2) in vitro and in vivo.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account

Product Details

Alternative Name	N-(4-Trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide, 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
Appearance	White solid.
CAS	108605-62-5
Couple Target	Dihydrorotate dehydrogenase
Couple Type	Inhibitor
Formula	C₁₂H₉F₃N₂O₂
Identity	Determined by NMR.
MW	270.2
Purity	≥98% (HPLC)
Solubility	Soluble in DMSO.

Handling & Storage

Use/Stability	As indicated on product label or CoA when stored as recommended.
Handling	Protect from light. Keep under inert gas.
Long Term Storage	+4°C
Shipping	Ambient Temperature

Regulatory Status	RUO – Research Use Only

RNA helicase DDX21 mediates nucleotide stress responses in neural crest and melanoma cells: Santoriello, C., Sporrij, A., et al.; Nat. Cell Biol. 22, 372 (2020), Abstract
Mitochondrial dysfunction induced by leflunomide and its active metabolite: J. Xuan, et al.; Toxicology 396, 33 (2018), Abstract — Full Text
A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner: L.C. Hamilton, et al.; Br. J. Pharmacol. 127, 1589 (1999), Abstract
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression: S.K. Manna & B.B. Aggarwal; J. Immunol. 162, 2095 (1999), Abstract
The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms: R.T. Elder, et al.; J. Immunol. 159, 22 (1997), Abstract
In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice: X. Xu, et al.; J. Immunol. 159, 167 (1997), Abstract
Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation: X. Xu, et al.; Biochem. Pharmacol. 52, 527 (1996), Abstract
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase: J.P. Davis, et al.; Biochemistry 35, 1270 (1996), Abstract
Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide: X. Xu, et al.; J. Biol. Chem. 270, 12398 (1995), Abstract — Full Text
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide: T. Mattar, et al.; FEBS Lett. 334, 161 (1993), Abstract

Related Products

Leflunomide

ALX-430-095

Immunosuppressant

22 citations

Alternative Name	HWA486, 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide), N-(4-Trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide
CAS	75706-12-6
Couple Type	Inhibitor
Purity	≥98.5% (HPLC)

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Datasheet

Certificate of Analysis

Please enter the lot number as featured on the product label

Lot No. :

SDS

Enzo Life Science provides GHS Compliant SDS

If your language is not available please fill out the SDS request form

Your Cart

Your Cart

A77 1726

ALX-430-096

Product Details

Handling & Storage

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Certificate of Analysis

SDS

Change Country

Tell us about You

Tell us about your paper

Tell us about You

Tell us about your project